NASDAQ:DFFN - Diffusion Pharmaceuticals Inc.
$3.12
 $-0.19
-5.74%
4:00PM EDT
2019-04-18
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, incorporated on June 17, 2015, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion' s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. The Company's clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer and brain metastases.The Company's TSC is designed to target the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  DFFN     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 07   199. 07   233. 87  
42 stocks rank:  4. 34 K 1. 43 K 1. 06 K
# analyst opinions:  1. 00   14. 48   14. 09  

quick ratio:  9. 94   5. 29   1. 92  
current ratio:  11. 09   5. 64   2. 40  

target price low:  3. 18   84. 50   115. 74  
target price avg:  3. 18   110. 73   137. 39  
target price high:  3. 18   136. 41   157. 80  
1-yr high:  8. 40   114. 11   138. 85  
last close:  3. 12   87. 56   116. 78  
50-day avg:  3. 78   95. 43   123. 53  
200-day avg:  4. 58   94. 13   121. 20  
1-yr low:  1. 94   72. 67   98. 41  
volume:  34. 90 K 2. 43 M 4. 85 M
50-day avg volume:  179. 89 K 2. 72 M 4. 97 M
200-day avg volume:  246. 11 K 2. 90 M 4. 58 M

1-day return:  -5. 74 % -0. 40 % 0. 07 %
this week return:  -9. 04 % -5. 72 % -4. 11 %
12-wk return:  38. 05 % 1. 78 % -0. 04 %
52-wk return:  -60. 00 % 10. 81 % 14. 09 %

enterprise value (EV):  3. 57 M 51. 19 B 117. 96 B
market cap:  10. 54 M 43. 00 B 104. 52 B
EBITDA:  -11. 92 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 30   4. 34   13. 27  
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -26. 62 M 2. 20 B 4. 21 B

shares outstanding:  3. 38 M 570. 91 M 1. 24 B
shares:  3. 18 M 571. 02 M 1. 23 B
shares short:  324. 57 K 9. 93 M 16. 79 M
shares short prior month:  62. 84 K 9. 96 M 16. 58 M
short ratio:  0. 88   5. 31   3. 30  
short % of float:  9. 90 % 5. 81 % 2. 61 %
total cash/share:  2. 37   11. 13   9. 30  
total cash:  7. 99 M 6. 70 B 7. 10 B
free cash flow:  -7. 63 M 3. 58 B 4. 74 B
operating cash flow:  -10. 77 M 4. 14 B 6. 32 B

book value:  4. 62   12. 76   26. 84  
price/book:  0. 67   3. 08   -1. 74  
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  55. 90 % --- ---
1-yr mean volatility:  -0. 17 % 0. 03 % 0. 04 %

1-yr EPS:  -8. 21   2. 39   4. 08  
forward EPS:  -2. 73   3. 97   7. 14  
P/E:  -0. 38   13. 59   22. 83  
forward P/E:  -1. 26   -20. 05   14. 49  
PE/G:  0. 01   -1. 46   1. 68  
growth:  -71. 26 % 126. 81 % 29. 29 %
earnings high:  -0. 91   1. 02   1. 63  
earnings avg:  -0. 91   0. 76   1. 51  
earnings low:  -0. 91   0. 47   1. 39  
revenue high:  -0. 00   2. 68 B 10. 71 B
revenue avg:  -0. 00   2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -33. 91 % -2. 80 % 5. 29 %
return on equity:  -99. 72 % -18. 52 % 7. 38 %

beta (1yr vs S&P500):  0. 51   1. 24   0. 93  
sharpe (1yr):  -0. 38   0. 29   0. 60  

held % insiders:  3. 37 % 6. 38 % 3. 38 %
held % institutions:  8. 88 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : DFFN
.        + 0 =             0 :: INITIAL WEIGHT
.   + 38.237 =        38.237 :: spline projection addition
.    x 1.432 =        54.757 :: industry recommendation factor
.    x 0.997 =        54.571 :: return on assets factor
.     x 0.99 =        54.027 :: return on equity factor
.    x 2.034 =       109.873 :: current ratio factor
.    x 1.054 =       115.856 :: quick ratio factor
.    x 1.507 =       174.559 :: short ratio factor
.    x 2.007 =       350.296 :: price-to-book factor
.    x 2.171 =       760.533 :: P/E weight
.    x 2.209 =      1679.987 :: PE/G factor
.    x 1.291 =      2168.907 :: beta factor
.    x 0.383 =       830.654 :: sharpe factor
.    x 1.139 =       946.481 :: target low factor
.    x 1.047 =       991.348 :: target mean factor
.    x 1.014 =      1005.446 :: target high factor
.    x 1.312 =      1318.792 :: industry 2-weeks return factor
.    x 0.636 =        838.55 :: overall "drift" factor
.    x 0.441 =       369.784 :: largest single-day jump factor
.    x 0.071 =          26.3 :: low price factor
.      x 1.0 =        26.296 :: factor hist industry gain for week 15
.   cubeRoot =         2.974 :: reduced to standardize
.   - 28.482 =         0.072 :: add/subtract for performance
.                      0.072 :: FINAL WEIGHT for NASDAQ:DFFN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org